3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Topotecan
10
Etoposide
7
Specimen Handling
6
berzosertib
5
Cisplatin
5
Biopsy
5
sargramostim
4
Platinum
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Carboplatin
4
trioctyl phosphine oxide
3
X-Rays
3
Paclitaxel
3
Nivolumab
3
1,2-diaminocyclohexaneplatinum II citrate
3
veliparib
2
romidepsin
2
olaparib
2
cabozantinib
2
aldesleukin
2
Tomography, X-Ray Computed
2
Temozolomide
2
Sunitinib
2
PM 01183
2
Electrocardiography
2
Depsipeptides
2
Decitabine
2
Cyclophosphamide
2
Budesonide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Small Cell Lung Carcinoma
×
Diagnostic Imaging
×
Clear all
NCT00047385
2014-05-20
NLST
National Cancer Institute (NCI)
Phase 3
Completed
53,454 enrolled
15 charts